← All Eli Lilly & CO filings

Eli Lilly & CO DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NYSE
LLY
Eli Lilly & CO
DEF: Eli Lilly Reports Strong 2025, Proposes Governance Reforms
Eli Lilly reports exceptional 2025 financial and pipeline performance, alongside proposals to enhance corporate governance for shareholder approval.
NYSE
LLY
Eli Lilly & CO
DEFA14A: Eli Lilly Files Definitive Additional Proxy Materials
Eli Lilly has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.
NYSE
LLY
Eli Lilly & CO
DEF: Eli Lilly Aims to Streamline Governance with Proposed Charter Amendments
Eli Lilly seeks shareholder approval to eliminate its classified board structure and supermajority voting provisions, enhancing corporate governance.
NYSE
LLY
Eli Lilly & CO
DEFA14A: Eli Lilly and Company Files Definitive Additional Proxy Materials
Eli Lilly and Company has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.
NYSE
LLY
Eli Lilly & CO
DEF 14A: Eli Lilly Aims for Governance Overhaul, Highlights Strong 2023 Performance
Eli Lilly's proxy statement details a push to eliminate its classified board and supermajority voting requirements, alongside a review of its strong 2023 financial and operational performance.